National Institute on Drug Abuse (NIDA)
methadone hydrochloride(National Institute on Drug Abuse (NIDA))은 Brain and Central Nervous System Tumors 표적 세포·유전자 치료로, Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders 영역에서 개발·상용화 중입니다. 작용기전: target MORs such as novel low-efficacy MOR agonists or long-acting formulations, and (3) medications that target post-MOR signaling. 전임상 단계입니다. 대표 임상 효능: ORR 13.7% (ClinicalTrials.gov NCT00386243). PK: t½ 2.0 h. 차별점: unique patient profiles.
Brain and Central Nervous System Tumors
Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders
Discontinued
unique patient profiles
target MORs such as novel low-efficacy MOR agonists or long-acting formulations, and (3) medications that target post-MOR signaling
DNA damage
biomarkers, long-term safety profiling, sex-specific responses, and real-world effectiveness studies
downregulation of survivin expression
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
National Institute on Drug Abuse (NIDA)
methadone hydrochloride(National Institute on Drug Abuse (NIDA))은 Brain and Central Nervous System Tumors 표적 세포·유전자 치료로, Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders 영역에서 개발·상용화 중입니다. 작용기전: target MORs such as novel low-efficacy MOR agonists or long-acting formulations, and (3) medications that target post-MOR signaling. 전임상 단계입니다. 대표 임상 효능: ORR 13.7% (ClinicalTrials.gov NCT00386243). PK: t½ 2.0 h. 차별점: unique patient profiles.
Brain and Central Nervous System Tumors
Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders
Discontinued
unique patient profiles
target MORs such as novel low-efficacy MOR agonists or long-acting formulations, and (3) medications that target post-MOR signaling
DNA damage
biomarkers, long-term safety profiling, sex-specific responses, and real-world effectiveness studies
downregulation of survivin expression
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.